Gain Therapeutics appoints C. Evan Ballantyne as CFO, effective April 10, 2023

Gain Therapeutics, Inc.

Appointment: C. Evan Ballantyne named CFO effective April 10, 2023; predecessor Salvatore Calabrese transitions.
Compensation: $350k base salary, 40% target bonus; inducement equity of 100,000 options at $4.79 (4-year vest) and 100,000 performance RSUs.
Performance RSUs: 50,000 vest upon extending cash runway 24 months; 50,000 vest upon stock price reaching $10.00 for 10 days VWAP.
Background: Ballantyne was CFO of OncXerna, Orchestra BioMed, Cerecin; raised millions in equity and structured >$200M partnership.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Salvatore Calabrese

Chief Financial Officer

GANX · Gain Therapeutics, Inc.

Effective: 2023-04-10
Successor: C. Evan Ballantyne
Filed: April 12, 2023, 7:59 PM ET

the Company informed Salvatore Calabrese, the Company’s former Chief Financial Officer, that his service as Chief Financial Officer of the Company would terminate effective as of the Transition Date.

Appointed

C. Evan Ballantyne

Chief Financial Officer

GANX · Gain Therapeutics, Inc.

Effective: 2023-04-10
Filed: April 12, 2023, 7:59 PM ET

announced the appointment of C. Evan Ballantyne as its Chief Financial Officer, effective as of April 10, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Salvatore Calabrese was terminated as Chief Financial Officer at Gain Therapeutics, Inc..

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

the Company informed Salvatore Calabrese, the Company’s former Chief Financial Officer, that his service as Chief Financial Officer of the Company would terminate effective as of the Transition Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

C. Evan Ballantyne was appointed as Chief Financial Officer at Gain Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

announced the appointment of C. Evan Ballantyne as its Chief Financial Officer, effective as of April 10, 2023

View on SEC.gov

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-044623

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.